Table 1 Mayo clinic TNBC cohort characteristics stratified by ERβ expression.
Characteristics | Range | ERβ positive (n = 102) | ERβ negative (n = 465) | p value |
|---|---|---|---|---|
Age (years) | <50 | 29 (28.4%) | 161 (34.6%) | 0.48 |
50–69 | 54 (52.9%) | 221 (47.5%) | ||
>70 | 19 (18.6%) | 83 (17.8%) | ||
BMI (kg/m2) | <25 | 40 (39.6%) | 171 (37.3%) | 0.84 |
25–29.9 | 32 (31.7%) | 159 (34.7%) | ||
≥30 | 29 (28.7%) | 128 (27.9%) | ||
Missing | 1 | 7 | ||
Histology | Apocrine differentiation | 6 (5.9%) | 29 (6.2%) | 0.23 |
Medullary features | 10 (9.8%) | 83 (17.8%) | ||
Metaplastic carcinoma | 9 (8.8%) | 35 (7.5%) | ||
Other | 77 (75.5%) | 318 (68.4%) | ||
Nottingham grade | 1–2 | 14 (13.7%) | 50 (10.8%) | 0.39 |
3 | 88 (86.3%) | 415 (89.2%) | ||
Maximum tumor dimension (cm) | at most 2.0 | 59 (57.8%) | 230 (49.6%) | 0.31 |
2.1–5.0 | 38 (37.3%) | 210 (45.3%) | ||
5.1 or larger | 5 (4.9%) | 24 (5.2%) | ||
Not stated | 0 | 1 | ||
Lymph node involvement | positive | 26 (26.0%) | 170 (37.1%) | 0.04 |
negative | 74 (74.0%) | 288 (62.9%) | ||
not evaluated | 2 | 7 | ||
Ki67 | ≤15% | 22 (22.0%) | 106 (23.5%) | 0.80 |
>15% | 78 (78.0%) | 346 (76.5%) | ||
not obtained | 2 | 13 | ||
Androgen Receptor | 0 | 55 (67.1%) | 273 (67.4%) | 0.87 |
1–15% | 5 (6.1%) | 20 (4.9%) | ||
≥15% | 22 (26.8%) | 112 (27.7%) | ||
not obtained | 20 | 60 | ||
Stromal TILs | 1–15% | 58 (56.9%) | 204 (44.4%) | 0.03 |
≥15% | 44 (43.1%) | 255 (55.6%) | ||
not obtained | 0 | 6 | ||
Chemotherapy type | Anthracycline-based | 26 (25.5%) | 96 (20.7%) | 0.009 |
Anthracycline/Taxane | 9 (8.8%) | 103 (22.2%) | ||
Taxane-based | 4 (3.9%) | 6 (1.3%) | ||
Non-Anthracycline/non-Taxane | 14 (13.7%) | 58 (12.5%) | ||
None/unknown | 49 (48.0%) | 202 (43.4%) |
